Entries by Sanne Lauriks

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

The investigational CAR T-cell therapy AZD0486 was associated with high complete response (CR) rates in patients with relapsed or refractory follicular lymphoma or patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), supporting further exploration of the drug. Follicular lymphoma “The investigational agent AZD0486 is a CD19 and CD3 bispecific T-cell engager,” said Dr […]